Skip to the main content

Original scientific paper

Relation between Intracavernosal Dose of Prostaglandin Pge 1 and Mean Duration of Erection in Men with Different Underlying Causes of Erectile Dysfunction

Dejan Bratuš
Gregor Hlebič
Tine Hajdinjak


Full text: english pdf 436 Kb

page 76-80

downloads: 654

cite


Abstract

Aim To analyze differences in effect of intracavernosally applied alprostadil (prostaglandin PGE 1) on men with different underlying causes of erectile dysfunction.
Methods Forty eight men with erectile dysfunction lasting for at least six months were stratified according to the etiology of erectile dysfunction into one of 4 groups comprising 12 patients. The groups were the following: psychogenic, arteriogenic, veno-occlusive, and neurological erectile dysfunction group. All men filled out International Index of Erectile Function (IIEF)-5 questionnaire, which is a 5-question version of International Index of Erectile Function Questionnaire, underwent clinical examination including neurological assessment, were tested for nocturnal penile tumescence, and had Doppler color sonography of penile arteries. Intracavernosal alprostadil was then applied to the patients, starting with a 5g dose and then increased in 5g increments until the final dose of 20g was reached. We measured the time from the moment of application until the start of erection and time of erection duration. For statistical analysis, non-parametric Friedman test for significant differences between repeated measurements in small groups and Wilcoxon test for differences between doses were used.
Results Significant relation was found between the applied dose of intracavernosal alprostadil and the duration of erection in all 4 groups of men with erectile dysfunction. In patients with arteriogenic erectile dysfunction, mean (±standard deviation) duration of erection for consecutive doses of alprostadil 5g, 10g, 15g, and 20g were 40.0±20.6, 54.6±23.6, 65.0±29.6, and 82.1±35.4 minutes, respectively, with significant increase for each dose. In

Keywords

erectile dysfunction; treatment; alprostadil; intracavernosal therapy

Hrčak ID:

9412

URI

https://hrcak.srce.hr/9412

Publication date:

20.2.2007.

Visits: 1.433 *